Michael Hayden

(Dr. Michael Hayden M.D., Ph.D.)

Currently holds positions in Aurinia Pharmaceuticals Inc, Ionis Pharmaceuticals Inc and Xenon Pharmaceuticals Inc

Positions
Position Company Period
Director Aurinia Pharmaceuticals Inc Feb. 22, 2018 -
Director Ionis Pharmaceuticals Inc Sept. 24, 2018 -
Independent Director Xenon Pharmaceuticals Inc Jan. 1, 1996 -
President - Global Research and Development, Chief Scientific Officer Teva Pharmaceutical Industries Ltd May 8, 2012 - Dec. 31, 2017
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PS: Planned sale, O: Option / Other
Notification date Transaction date B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Total value Details
2023-09-26 2023-09-22
B Purchase
20,000 +1.5%
4.91
98,200 USD 		20,000 +1.5% 4.91 98,200 USD
2023-08-09 2023-08-08
B Purchase
30,000 +2.4%
5.90
177,000 USD 		30,000 +2.4% 5.90 177,000 USD
2023-03-30 2023-03-28
US 89Bio Inc (ETNB)
B Purchase
61,538 +inf%
16.15
993,839 USD 		61,538 +inf% 16.15 993,839 USD
2023-03-30 2022-04-07
US 89Bio Inc (ETNB)
B Purchase
10,000 +11.9%
3.48
34,750 USD 		10,000 +11.9% 3.48 34,750 USD
2023-03-30 2022-03-30
US 89Bio Inc (ETNB)
B Purchase
6,250 +8.0%
3.62
22,625 USD 		6,250 +8.0% 3.62 22,625 USD
2021-06-22 2021-06-22
S Sale
100,000 -9.1%
25.50
2,550,000 USD 		100,000 -9.1% 25.50 2,550,000 USD
2020-12-17 2020-12-15
B Purchase
73,665 +165.2%
20.00
1,473,300 USD 		73,665 +165.2% 20.00 1,473,300 USD